A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)

被引：0
|
作者：
Hamilton, E. P. [1 ]
Bagegni, N. A. [2 ]
Beck, J. T. [3 ]
Cultrera, J. L. [4 ]
Dosunmu, O. [5 ]
Gwin, W. R. [6 ]
Heeke, A. L. [7 ]
Khoury, K. [8 ]
Sellami, D. [9 ]
Shastry, M. [10 ]
Sternberg, D. W. [11 ]
Toppmeyer, D. [12 ]
Wright-Browne, V. M. [13 ]
Yuan, Y. [14 ]
机构：
[1] Sarah Cannon Res Inst Canc Ctr, Drug Dev Unit, Nashville, TN USA
[2] Ctr Adv Med, Siteman Canc Ctr, St Louis, MO USA
[3] Highlands Oncol, Med Oncol, Springdale, AR USA
[4] Florida Canc Specialists North, Villages Canc Ctr, The Villages, FL USA
[5] Sarah Cannon Res Inst, Dev Innovat, Nashville, TN USA
[6] Canc Vaccine Inst Univ Washington, Med, Seattle, WA USA
[7] Levine Canc Inst Morehead, Breast & Surg Oncol, Charlotte, NC USA
[8] Univ Alabama Birmingham, Div Hematol & Oncol, ONeal Comprehens Canc Ctr 8, Birmingham, AL USA
[9] Daiichi Sankyo Inc, Oncol Dept, Basking Ridge, NJ USA
[10] Sarah Cannon Res Inst, Strateg Dev Dept, Nashville, TN USA
[11] Daiichi Sankyo Inc, Oncol R&D, Basking Ridge, NJ USA
[12] Rutgers Canc Inst New Jersey, Med Oncol, New Brunswick, NJ USA
[13] Florida Canc Specialists, Port Charlotte, FL USA
[14] City Hope Natl Med Ctr, Med Oncol & Therapeut Res, Duarte, CA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
204TiP
引用
收藏
页码：S220 / S220
页数：1
相关论文
共 50 条
  • [31] Pulmonary toxicities in patients (pts) with metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd): The Mayo Clinic experience
    Hoppenworth, Jenna
    Premji, Sarah
    Smith, Deanne R.
    Taraba, Jodi L.
    Hobday, Timothy J.
    Peethambaram, Prema P.
    Carroll, Jamie
    Ruddy, Kathryn Jean
    O'Sullivan, Ciara Catherine
    Tevaarwerk, Amye Juliet
    Choong, Grace Mei Yee
    Cathcart-Rake, Elizabeth Jane
    Yadav, Siddhartha
    Ellsworth, Lisa
    Rao, Rohit
    Egan, Ashley
    Haddad, Tufia C.
    Goetz, Matthew P.
    Giridhar, Karthik
    Leon-Ferre, Roberto Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] A PHASE-II STUDY OF CHIP IN METASTATIC BREAST-CANCER (MBC)
    HORTOBAGYI, G
    HOLMES, F
    FRYE, D
    HUG, V
    FRASCHINI, G
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 198 - 198
  • [33] Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC)
    Yuan, Qianyu
    Castellanos, Emily
    Fidyk, Erin
    Schwed, Karen
    Estevez, Melissa
    Nemeth, Sheila
    Linzmayer, Robin
    Cohen, Aaron B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
    Powell, C. A.
    Modi, S.
    Iwata, H.
    Takahashi, S.
    Nie, K.
    Qin, A.
    Singh, J.
    Taitt, C.
    Verma, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S61 - S62
  • [35] PHASE II STUDY OF IRINOTECAN (CPT-11) IN PATIENTS (PTS) WITH PREVIOUSLY TREATED METASTATIC BREAST CANCER (MBC): KMBOG0601
    Hayashi, H.
    Tsurutani, J.
    Satoh, T.
    Sakamoto, J.
    Masuda, N.
    Tokunaga, Y.
    Yamaguchi, M.
    Tominaga, S.
    Fukuoka, M.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 121 - 121
  • [36] Phase II randomized study of capecitabine (C) administered as continuous versus standard (cyclic) treatment in patients (PTS) with metastatic breast cancer (MBC)
    Martin, Miguel
    Casado, A.
    Garcia-Saenz, J. A.
    Calvo, Lourdes
    Constenla, Manuel
    Diaz-Rubio, E.
    ANNALS OF ONCOLOGY, 2006, 17 : 74 - 74
  • [37] Interim analysis of a Phase II study of biochemotherapy in metastatic breast cancer (MBC)
    Lal, A.
    Alidina, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 131 - 131
  • [38] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joohyuk
    Vidal, Maria
    Tokunaga, Eriko
    Tsurutani, Junji
    Ueno, Naoto T.
    Chae, Yee Soo
    Lee, Keun Seok
    Niikura, Naoki
    Park, Yeon Hee
    Wang, Xiaojia
    Xu, Binghe
    Gambhire, Dhiraj
    Yung, Lotus
    Meinhardt, Gerold
    Wang, Yibin
    Harbeck, Nadia
    Cameron, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [39] Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
    Saura Manich, C.
    Modi, S.
    Krop, I.
    Park, Y. H.
    Kim, S-B.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Singh, J.
    Yamashita, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S485 - S486
  • [40] Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Peacock, N. W.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Greco, F. A.
    Farley, C.
    Webb, C.
    Spigel, D. R.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345